Icon

NOVANTRONE (nda019297)- (EQ 20MG BASE/10ML (EQ 2MG BASE/ML),EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML),EQ 30MG BASE/15ML (EQ 2MG BASE/ML))

MITOXANTRONE HYDROCHLORIDE EMD SERONO
EQ 20MG BASE/10ML (EQ 2MG BASE/ML),EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML),EQ 30MG BASE/15ML (EQ 2MG BASE/ML)
No No
2006-Apr-11 Expired
None None
None No
NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses).
4 0 3
Total Other Developers None
Drugs with Suitability No
EQ 20MG BASE/10ML (EQ 2MG BASE/ML) ** ** - - -
EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) ** ** - - -
EQ 30MG BASE/15ML (EQ 2MG BASE/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ******* ********* *** *** *********** *-** ***** **, ********, ******** ****, ********* (***) ***
****** ******* ***** ******* ******** ******* ******* *********** **** **.*, *******, ******* ******** ****, ******* ***** *******, ******* ******, ****** ******, *********, ******* ******, ***** (***) ***
****** ********* **** *** ********* **** ***, *** *********** **** *. **** ****** **** ***** ********* ******, ******* ****, ******** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.